Protagonist Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period
Protagonist is a clinical-stage biopharmaceutical company developing constrained peptide-based drug candidates in hematology and gastroenterology. This unaudited Form 10-Q covers the three months ended March 31, 2019, with comparison to the three months ended March 31, 2018. The company had 23,396,033 common shares outstanding as of April 30, 2019.
- PTG-300: Phase 2 beta-thalassemia study began dosing in the first quarter of 2019; top-line results were expected in the second half of 2019.
- PTG-200: Licensed and developed with Janssen for inflammatory bowel disease; Janssen was expected to file a U.S. IND in the second quarter of 2019.
- PN-943: Phase 1 study in healthy volunteers; top-line results were expected in the second quarter of 2019, with a potential IND filing in late 2019.
Financial performance and liquidity
| Metric | Q1 2019 | Q1 2018 | Change |
|---|---|---|---|
| License and collaboration revenue | $1.6 million | $10.8 million | Down $9.2 million, or 86% |
| Research and development expense | $12.4 million | $15.4 million | Down $2.9 million, or 19% |
| General and administrative expense | $3.8 million | $3.6 million | Up $0.1 million, or 3% |
| Loss from operations | $(14.6) million | $(8.2) million | Loss increased $6.4 million |
| Interest income | $0.7 million | $0.6 million | Up $0.2 million |
| Net loss | $(14.1) million | $(7.7) million | Loss increased $6.4 million |
| Basic and diluted net loss per share | $(0.58) | $(0.36) | More loss per share |
| Net cash used in operating activities | $(16.7) million | $(15.1) million | Use increased $1.5 million |
- Cash and cash equivalents were $70.1 million at March 31, 2019; available-for-sale securities were $42.5 million. Combined cash, cash equivalents and available-for-sale securities totaled $112.5 million, compared with $128.9 million at December 31, 2018.
- Cash, cash equivalents and restricted cash declined by $12.2 million during the quarter to $70.5 million.
- Total assets were $132.2 million and stockholders’ equity was $100.8 million at March 31, 2019.
- Accumulated deficit was $154.6 million. The company has incurred losses since inception and expects additional losses.
- The company reported no outstanding debt or credit facility.
- Management stated that existing cash, cash equivalents and available-for-sale securities were expected to fund operations and capital expenditures for at least the next 12 months, but substantial additional capital will be required for continued clinical development and potential commercialization.
Material changes versus the prior comparable period
- Revenue declined primarily because recognition of the $50.0 million Janssen upfront payment was nearing completion. Revenue in Q1 2019 was primarily based on proportional performance and remaining cost-sharing and supply activities.
- Research and development spending shifted materially among programs: PTG-100 expense decreased by $8.4 million after its development was halted; PTG-943 expense was $4.2 million; PTG-300 expense increased by $3.2 million to $5.8 million; and PTG-200 expense decreased by $2.1 million to $1.1 million.
- Stock-based compensation increased to $2.0 million from $1.2 million.
- Operating cash use increased despite lower research and development expense, partly reflecting changes in accrued expenses, deferred revenue and collaboration-related balances.
- Effective January 1, 2019, adoption of ASC 842 resulted in recognition of a $6.8 million operating lease right-of-use asset and $8.0 million of operating lease liabilities at March 31, 2019. The adoption was substantially balance-sheet presentation related.
Guidance, outlook, commentary, risks and unusual items
- Management does not expect sustained profitability in the near term and expects research, development and other operating expenses to continue increasing as programs advance.
- The company expects to raise additional capital through equity, debt, collaboration or other financing arrangements. Future financing may dilute existing stockholders or be unavailable on acceptable terms.
- On May 7, 2019, after the reporting period, the company amended its Janssen agreement. Janssen became obligated to pay a $25.0 million milestone payment, and the amendment added support for second-generation IL-23 receptor antagonists and eligibility for more than $1.0 billion of additional research, development, regulatory and sales milestones. These subsequent-event terms were not reflected in the March 31, 2019 financial statements.
- The original Janssen agreement included a potentially payable $25.0 million IND filing milestone, but it remained fully constrained at March 31, 2019 because the filing was not considered probable.
- Key risks include clinical-trial failure or delay, patient enrollment challenges, regulatory nonapproval, manufacturing and third-party contractor dependence, collaboration termination or disagreements with Janssen, intellectual-property challenges, competition, and the need for substantial additional financing.
- The company has no approved products and no product sales revenue. Its future value depends heavily on clinical and regulatory success and continued collaboration funding.
- Management reported effective disclosure controls and procedures and no material changes to internal control over financial reporting during the quarter. The company reported no material legal proceedings.
Important facts for investors to verify
- Timing and outcome of Janssen’s PTG-200 IND filing and receipt of the $25.0 million milestone payment under the May 2019 amendment.
- Progress and results of the PTG-300 Phase 2 beta-thalassemia study, including the anticipated second-half 2019 data.
- PN-943 Phase 1 results and the timing of any late-2019 IND filing.
- Remaining duration and amount of Janssen-related revenue recognition, including the $7.0 million deferred revenue balance at March 31, 2019.
- Cash burn, the duration of the stated liquidity runway, and the timing and terms of any future financing.
- Janssen’s future opt-in decisions, collaboration performance, and the risk that the agreement could terminate or fail to generate milestone or royalty payments.